Your browser doesn't support javascript.
loading
Poly(allylamine)-adorned heptylcarboxymethyl galactomannan nanocarriers of canagliflozin for controlling type-2 diabetes: Optimization by Box-Behnken design and in vivo performance.
Yadav, Harsh; Maiti, Sabyasachi.
Afiliación
  • Yadav H; Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh 484887, India.
  • Maiti S; Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh 484887, India. Electronic address: sabya245@rediffmail.com.
Int J Biol Macromol ; 277(Pt 2): 134253, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39084426
ABSTRACT
In the past three decades, the prevalence of type-2 diabetes has arisen dramatically in countries of all income levels. A novel, most effective nanotechnology-based strategy may reduce the prevalence of diabetes. Recently, the shell-crosslinked polysaccharide-based micellar nanocarriers (MNCs) have shown great promise in terms of stability, controlled drug release, and improved in vivo performance. In this study, heptyl carboxymethyl guar gum was synthesized and characterized by ATR-FTIR, 1HNMR spectroscopy, surface charge, critical micelle concentration (23.9 µg/mL), and cytotoxicity analysis. Box-Behnken design was used to optimize the diameter, zeta potential, drug entrapment efficiency (DEE), and drug release characteristics of poly (allylamine)-crosslinked MNCs containing canagliflozin. The optimized MNCs revealed spherical morphology under TEM and had 149.3 nm diameter (PDI 21.2 %), +53.8 mV zeta potential, and 84 % DEE. The MNCs released about 63 % of the drug in 12 h under varying pH of the simulated gastrointestinal fluid. DSC and x-ray analyses suggested amorphous dispersion of drugs in the MNCs. CAM assay demonstrated the biocompatibility of the MNCs. The MNCs showed hemolysis of <1 %, 85 % mucin adsorption, and stability over three months. The MNCs demonstrated excellent anti-diabetic efficacy in streptozotocin-nicotinamide-induced diabetic rats, continuously lowering blood glucose levels up to 12 h.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Poliaminas / Portadores de Fármacos / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Canagliflozina / Galactosa / Mananos Límite: Animals Idioma: En Revista: Int J Biol Macromol Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Poliaminas / Portadores de Fármacos / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Canagliflozina / Galactosa / Mananos Límite: Animals Idioma: En Revista: Int J Biol Macromol Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Países Bajos